TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30907817
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (10,000 IU/day)
Study: 22866292
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg quick-release lornoxicam (LNX)
Study: 26043913
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training (PFMT), electrical stimulation (ES), biofeedback plus 1 mg intravaginal estriol (IE)
Study: 22999793
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/d)
Study: 19915017
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg/d)
Study: 3007984
Drug: Neither treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither treatment
Study: 16625988
Drug: Almotriptan 25
Normalized name: almotriptan 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 25 mg under fasting condition (reference)
Study: 16625988
Drug: Almotriptan 25
Normalized name: almotriptan 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 25 mg under fed condition
Study: 16625988
Drug: Almotriptan 25
Normalized name: almotriptan 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 25 mg under fasting and fed conditions
Study: 1582275
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ODI, HVI, ISI
Study: 2414580
Drug: Guanfacine 3
Normalized name: guanfacine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine 3 mg infused over 1 h
Study: 2414580
Drug: Idazoxan 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan 0.2 mg/kg i.v. (control)
Study: 15450785
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/day) for 6 weeks
Study: 8636370
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH administered sc daily at bedtime, target dose of 12 micrograms/kg x day
Study: 1763227
Drug: CDP-choline 2000
Normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline 2000 mg/die e.v. from two weeks before surgery to ten days after surgery, then 1000 mg/die i.m., 15 days per month for 6 months (Group A)
Study: 1763227
Drug: CDP-choline 100
Normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline 100 mg/die from two weeks before surgery to six months after surgery (Group B)
Study: 6814227
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 to 320 mg/day)
Study: 6814227
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 to 480 mg/day)
Study: 3878652
Drug: Isoflurane administered
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane administered at an inspired concentration of 0.5‐1.5% for 30 minutes after CPB.
Study: 29091471
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BRJ) supplementation (70-ml concentrated, 7.7 mmol)
Study: 24515273
Drug: AP301 (inhaled,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP301 (inhaled, single doses up to 120 mg)
Study: 22563773
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg once daily
Study: 1792912
Drug: Triple intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple intrathecal injections (TIT)
Study: 30358831
Drug: DP1-10 cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP1-10 cocoa extract containing 130 mg (‐)‐epicatechin and 560 mg procyanidins
Study: 30358831
Drug: DP2-10 cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP2-10 cocoa extract containing 20 mg (‐)‐epicatechin and 540 mg procyanidins
Study: 17378788
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia plus intrathecal MgSO(4) (94.5 mg, 6.3%)
Study: 9505567
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) used off-label in conjunction with antibiotics
Study: 30790069
Drug: Pegilodecakin monotherapy
Normalized name: ilodecakin
DrugBank: Ilodecakin (DB06449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegilodecakin monotherapy
Study: 25731073
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention (one-page information sheet about hydrocodone-acetaminophen, given and read aloud)
Study: 23062389
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol 320 mg/d
Study: 15110882
Drug: Droperidol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (2.5 mg d.i.v. twice daily for 5 days) combined with granisetron (3 mg d.i.v. on the first day) and dexamethasone (16 mg d.i.v. on the first day, 8 mg d.i.v. on days 2, 3, and 4)
Study: 15110882
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with granisetron (3 mg d.i.v. on the first day) and dexamethasone (16 mg d.i.v. on the first day, 8 mg d.i.v. on days 2, 3, and 4)
Study: 15110882
Drug: Droperidol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (2.5 mg d.i.v. twice daily for 5 days)
Study: 8239224
Drug: Hydroxychloroquine, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine, 400 mg daily
Study: 15066608
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups combined
Study: 15613917
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g glucose
Study: 22363492
Drug: Psilocybin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psilocybin administration
Study: 15900306
Drug: Statin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (20 mg lovastatin)
Study: 363629
Drug: Mazindol (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (two preparations)
Study: 31255591
Drug: Biannual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual mass drug administration (MDA) with praziquantel alone (arm 1)
Study: 31255591
Drug: Biannual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual mass drug administration (MDA) with snail control (arm 2)
Study: 31255591
Drug: Biannual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual mass drug administration (MDA) with behaviour change activities (arm 3)
Study: 15566075
Drug: Magnetocardiogram (MCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetocardiogram (MCG)
Study: 2661768
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine plus azathioprine plus prednisolone (group A)
Study: 21748765
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg three times a day
Study: 19916995
Drug: Voriconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (400 mg)
Study: 9314127
Drug: Propranolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.15 mg/kg i.v., n = 60)
Study: 2425156
Drug: Propranolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.15 mg/kg i.v.)
Study: 3378554
Drug: Suxamethonium administration
Normalized name: suxamethonium
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suxamethonium administration with inhalation induction without pre-treatment
Study: 29582734
Drug: Norovirus vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norovirus vaccine interest survey
Study: 20876596
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml of sucrose 24% given by mouth using a syringe and a soother
Study: 20876596
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml of sterile water given by mouth using a syringe and a soother (Control)
Study: 28657793
Drug: Simvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (80 mg)
Study: 18376000
Drug: Simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin plus Ezetimibe (10 mg)
Study: 11053614
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (2 g daily)
Study: 24447354
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular heparin 4 kU once a day for 7 days
Study: 10827333
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive (OC)
Study: 2828818
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg naloxone
Study: 25203332
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine 0.5 mg/kg (Group K)
Study: 25203332
Drug: IV tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tramadol 0.5 mg/kg (Group T)
Study: 22753773
Drug: Tocilizumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (both doses)
Study: 16192421
Drug: High-dose hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hemodialysis
Study: 12037147
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin.
Study: 12037147
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous ultralente insulin
Study: 444954
Drug: Two-drug regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug regimen (vinblastine and procarbazine)
Study: 444954
Drug: Four-drug regimen
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug regimen (MVPP)
Study: 26188373
Drug: PST with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PST with weekly support (n = 106)
Study: 19154656
Drug: Placebo/Ketamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/Ketamine (0.3 mg/kg i.v.)
Study: 19154656
Drug: Haloperidol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2 mg)/Ketamine (0.3 mg/kg i.v.)
Study: 18589555
Drug: Epoetin zeta
Normalized name: Epoetin zeta
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin zeta (10,000 IU, intravenous bolus injection)
Study: 18589555
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (10,000 IU, intravenous bolus injection)
Study: 15760929
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg IM depomedrone
Study: 26466021
Drug: Drug-coated stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated stent (umirolimus-coated)
Study: 23122684
Drug: CIDR‐4 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIDR‐4 treatment (controlled internal drug release)
Study: 23122684
Drug: eCG+ECP (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: eCG+ECP (200 IU im eCG plus 0.5 mg ECP im)
Study: 23122684
Drug: ECP (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECP (0.5 mg)
Study: 16339823
Drug: L-NG-monomethyl-L-arginine (L-NMMA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NG-monomethyl-L-arginine (L-NMMA; 8 micromol/min)
Study: 12972844
Drug: Normative Treatment
Normalized name: K Norm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normative Treatment Planning (NTP) program
Study: 11069453
Drug: Cryotherapy (liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy (liquid nitrogen spray, two freeze-thaw cycles, each freeze for 5-10 seconds)
Study: 6360055
Drug: Nifedipine in
Normalized name: nifedipine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine in cardioplegic solution
Study: 18625352
Drug: Protocol A-1
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A-1 (540 mg I/kg body weight, imaging delay 15s)
Study: 18625352
Drug: Protocol A-2
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A-2 (540 mg I/kg body weight, imaging delay 18s)
Study: 18625352
Drug: Protocol A-3
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A-3 (540 mg I/kg body weight, imaging delay 21s)
Study: 7899404
Drug: Captopril (1.5-2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (1.5-2.0 mg/h i.v.)
Study: 1971504
Drug: Interferon-alpha 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha 4.5 million U/d with zidovudine 200 mg every 4 hours
Study: 1971504
Drug: Baseline CD4
Normalized name: CD4 IgG
DrugBank: Recombinant human CD4 immunoglobulin G (DB17812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline CD4 counts below 200 x 10(6) cells/L
Study: 24618069
Drug: DES ODF
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES ODF (2.0 mg)
Study: 22545363
Drug: Hydro alcoholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydro alcoholic nettle extract (100 mg kg(‐1) for 8 weeks)
Study: 9797905
Drug: Physiotherapeutic training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapeutic training twice a week for 10 weeks
Study: 8559437
Drug: Goserelin 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.2 mg given as a depot every 28 days for 6 months
Study: 8559437
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 10 mg from day 16 to day 25 of each month for 6 months
Study: 2558701
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (100 micrograms - 4000 micrograms)
Study: 2558701
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (identical dose protocol) in young subjects (24 +/- 3 years)
Study: 26457099
Drug: Acetate Mafenide
Normalized name: Mafenide Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate Mafenide ointment (8.5%)
Study: 16686813
Drug: Shared decision-making
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shared decision-making training for opioid treatment (n=22)
Study: 11271343
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal
Study: 16157935
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care alone (no chemotherapy)
Study: 16157935
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and Supportive care
Study: 12699097
Drug: Cefoxitin 2
Normalized name: cefoxitin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 2 g intravenously (randomised study)
Study: 2502256
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol given in doses that reduced the resting pulse rate by 25%
Study: 29258111
Drug: Clarithromycin-based triple
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin-based triple therapy (EAC group)
Study: 25959199
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (RAS inhibitor only)
Study: 23631971
Drug: Quad-helix/crib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quad-helix/crib treatment
Study: 19392993
Drug: Probiotic bacteria
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic bacteria (Bifidobacterium bifidum, Bifidobacterium lactis, Lactococcus lactis; Ecologic Panda) administered prenatally to mothers and to their offspring for the first 12 months of life
Study: 15474245
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg 17beta-estradiol with 10 mg dydrogesterone (HRT)
Study: 15474245
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg 17beta-estradiol without dydrogesterone (ERT)
Study: 9311477
Drug: No transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No transfusion with portal infusion of chemotherapy
Study: 2447687
Drug: Cimetidine 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1,200 mg/day
Study: 6092288
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg/day
Study: 2802120
Drug: No H2-receptor
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No H2-receptor antagonist (control)
Study: 30179720
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg daily from a month before surgery to 12 months after surgery)
Study: 30179720
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (20 μg of teriparatide daily and 60 mg denosumab every 6 months)
Study: 28316464
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of ropivacaine 1%
Study: 28316464
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of ropivacaine 1%
Study: 12844280
Drug: Conventional antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotics
Study: 16832128
Drug: Polidocanol injections
Normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polidocanol injections in the area of neovascularization
Study: 16832128
Drug: Lidocaine/epinephrine injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/epinephrine injections (control group)
Study: 16832128
Drug: Polidocanol injections
Normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polidocanol injections (after crossover for control group)
Study: 16832128
Drug: Polidocanol injections
Normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polidocanol injections (treatment group)
Study: 8889459
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 3 mg oral pH-modified release budesonide (BUD)
Study: 1894864
Drug: Angioplasty followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Angioplasty followed by a 30‐min intracoronary infusion of Fluosol at 40 ml/min
Study: 6189412
Drug: Dextran 6%
Normalized name: Dextran 6%, Dextrose 5% Solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 6% 500 ml
Study: 27471039
Drug: Antioxidant and
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant and zinc supplements
Study: 22111942
Drug: Lanreotide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide (120 mg/month)
Study: 20797478
Drug: Freeze-dried strawberry
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried strawberry beverage (50 g freeze-dried strawberries approximately 3 cups fresh strawberries)
Study: 16879079
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy and interpersonal psychotherapy
Study: 16879079
Drug: Adjunctive sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive sleep interventions (suggested)
Study: 16239176
Drug: Leisure-time physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leisure-time physical activity at midlife at least twice a week
Study: 3767388
Drug: Betamethasone (B)
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone (B) - 8 mg/body on day 1, 4 mg/body on days 2 and 3
Study: 18450876
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy with laxatives
Study: 1288797
Drug: Implant-supported prosthesis
Normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported prosthesis
Study: 9393430
Drug: Different implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different implant designs
Study: 1288797
Drug: Different implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different implant applications
Study: 1288797
Drug: Individual implants
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual implants regarding jaw location
Study: 1288797
Drug: Implant designs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant designs
Study: 29247636
Drug: Electronic-delivered screening,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic-delivered screening, brief intervention and referral to treatment
Study: 29247636
Drug: Clinician-delivered screening,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-delivered screening, brief intervention and referral to treatment
Study: 24582019
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (biofilm disclosing tablets)
Study: 24582019
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (combination of A and B)